Cargando…
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma
Melanoma is the most biologically aggressive skin cancer of well established constitutive and induced resistance to pharmacological treatment. Despite the recent progresses in immunotherapies, many advanced metastatic melanoma patients still face a significant mortality risk. The aggressive nature o...
Autores principales: | Capone, Emily, Giansanti, Francesco, Ponziani, Sara, Lamolinara, Alessia, Iezzi, Manuela, Cimini, Annamaria, Angelucci, Francesco, Sorda, Rossana La, Laurenzi, Vincenzo De, Natali, Pier Giorgio, Ippoliti, Rodolfo, Iacobelli, Stefano, Sala, Gianluca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707031/ https://www.ncbi.nlm.nih.gov/pubmed/29221137 http://dx.doi.org/10.18632/oncotarget.20728 |
Ejemplares similares
-
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma
por: Dufrusine, Beatrice, et al.
Publicado: (2023) -
Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma
por: Capone, Emily, et al.
Publicado: (2020) -
Antibody-Drug Conjugates: The New Frontier of Chemotherapy
por: Ponziani, Sara, et al.
Publicado: (2020) -
Aptamer-Driven Toxin Gene Delivery in U87 Model Glioblastoma Cells
por: di Leandro, Luana, et al.
Publicado: (2021) -
Taking Advantage of the Morpheein Behavior of Peroxiredoxin
in Bionanotechnology
por: Ardini, Matteo, et al.
Publicado: (2021)